percorso neuro-muscolare per PDF 08-02-11 - Policlinico S.Orsola ...

10. Di Nardo G, Blandizzi C, Volta U, Colucci R, Stanghellini V, Barbara G, Del Tacca M, Tonini M, Corinaldesi R,
De Giorgio R. Review article: molecular, pathological and therapeutic features of human enteric neuropathies.
Aliment Pharmacol Ther 2008; 28: 25-42.
11. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J
2007;28:2375–2414.
12. Fanin M, Nascimbeni AC, Fulizio L, Angelini C. The frequency of limb girdle muscular dystrophy 2A in
northeastern Italy. Neuromuscul Dirsord 2005;15(3):218-224.
13. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir
Crit Care Med 2007;28(4):451-458.
14. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006;253 (Suppl 5): V/2-V/8.
15. Fuglsang-Frederiksen A. The role of different EMG methodsin evaluating myopathy. Clin Neurophysiol
2006;117/6):1173-1189.
16. Gilhuis HJ, ten Donkelaar HJ, Tanke RB, Vingerhoets DM, Zwarts MJ, Verrips A, Gabreëls FJ. Nonmuscolar
involvement in merosine-negative congenital muscolar dystrophy. Pediatr Neurol. 2002 Jan;26(1):30-6.
17. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment. Panel III.
Guidelines. J Am Coll Cardiol 2004;44:720-32.
18. Izzo KL, Aravabhumi S. Clinical electromyography. Priciples and practice. Clin Pediatr Med Surg
1990;7(1):179-194.
19. Jacobson TA. Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of
Mialgia. Mayo Clinic Proc 2008;83(6):687-700.
20. Liguori R, Fuglsang-Frederiksen A, Nix W, Fawcett PR, Andersen K. Electromyography in myopathy.
Neurophysiol Clin 1997;27(33):200-203.
21. Lindermann E et al. Quadriceps strength and timed motor performances in myotonic dystrophy Charcot –Marie-
Tooth disease, and healthy subjects. Clin Rehabil 1998;12:127-135.
22. Lindermann E et al. strength training in patients with myotonic dystrophy and hereditary motor and sensory
neuropathy: A Randomized Clinical Trial. Arch Phys Med Rehabil;1993,76:612-620.
23. Lodi R and Taivassalo T. Phosphorus MR spectroscopy in the clinical investigation of muscle disorders. In:
Clinical evaluation and diagnostic tests for neuromuscular disorders. Bertorini T Ed. Butterworth-Heinemann
Publishers 2002:503-534.
24. McKenney JM. Statins, Cardiovascular Disease, and Drug Safety. Am J Card 2006;87(A):1c-97c.
25. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular
disorders: past, present, and future. J Magn Reson Imaging. 2007;25:433-40.
26. Milner-Brown HS et al. Muscle strenghtening through high resistence weight training in patients with
neuromuscular disorders. Arch Phys Med Rehabil. 1988;69:14-19.
27. Mochimaru H, Kawamoto M, Enomoto T, Saitoh Y, Abe S, Nei T, Fukuda Y, Kudoh S. Transbronchial biopsy is
clinically useful in classifying patients with interstitial pneumonia associated with polymyositis and
dermatomyositis. Respirology 2008; 13(6):863-870.
28. Molokhia M, McKeigue, Curcin V, Majeed A. Statin induced myopathy and myalgia. Time trend analysis and
comparison of risk associated with statin class from 1991-2006. PloSone 2008;3(6)2522:1-4.
29. Nirkko AC, Rosler KM, Hess CW. Sensitivity and specificity of needle electromyography: a prospective study
comparing automated interference pattern analysis with single motor unit potential analysis. Electroencephalogr
Clin Neurophysiol 1995;97(1):1-10.
30. Sackley L, Disler PB, Turner-Stokes L, Wade DT. Rehabilitation intervention for foot drop in neuromuscular
disease. Cochrane Database System Review, 2007 April 18.
31. Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion. 2008 May 23.
[Epub ahead of print].
17